Overview

A Study to Evaluate the Safety, Tolerability and Efficacy of Oral Administration of PTL101 (Cannabidiol) as an Adjunctive Treatment for Pediatric Intractable Epilepsy

Status:
Completed
Trial end date:
2018-06-28
Target enrollment:
Participant gender:
Summary
To evaluate the safety, tolerability and efficacy of oral administration of PTL101 (cannabidiol) for the treatment for pediatric intractable epilepsy. Study will include a 4-week observation period ,12 weeks of treatment and 2 weeks of follow up.
Phase:
Phase 2
Details
Lead Sponsor:
PhytoTech Therapeutics, Ltd.